{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:08Z","timestamp":1788250448308,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00415-018-9160-9","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T10:59:24Z","timestamp":1546513164000},"page":"806-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults"],"prefix":"10.1007","volume":"266","author":[{"name":"The OFSEP Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Cobo-Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The REEM Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyacintha","family":"d\u2019Indy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Armangu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Durand-Dubief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thouvenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Montcuquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Sol\u00e0-Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Llufriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"9160_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474\u2013481","journal-title":"Neurology"},{"key":"9160_CR2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R, Sepulveda M, Armangue T et al (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21:866\u2013874","journal-title":"Mult Scler"},{"key":"9160_CR3","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128\u20133138","journal-title":"Brain"},{"key":"9160_CR4","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90:e1858\u2013e1869","journal-title":"Neurology"},{"key":"9160_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"E-M Hennes","year":"2017","unstructured":"Hennes E-M, Baumann M, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900\u2013908","journal-title":"Neurology"},{"key":"9160_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","volume":"86","author":"M Baumann","year":"2015","unstructured":"Baumann M, Sahin K, Lechner C et al (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86:265\u2013272","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9160_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","volume":"264","author":"\u00c1 Cobo-Calvo","year":"2017","unstructured":"Cobo-Calvo \u00c1, Ruiz A, D\u2019Indy H et al (2017) MOG antibody-related disorders: common features and uncommon presentations. J Neurol 264:1945\u20131955","journal-title":"J Neurol"},{"key":"9160_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13:279","journal-title":"J Neuroinflammation"},{"key":"9160_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"J-W Hyun","year":"2017","unstructured":"Hyun J-W, Woodhall MR, Kim S-H et al (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 88:811\u2013817","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9160_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J et al (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 75:1355\u20131363","journal-title":"JAMA Neurol"},{"key":"9160_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"9160_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/1352458512466317","volume":"19","author":"P Huppke","year":"2013","unstructured":"Huppke P, Rostasy K, Karenfort M et al (2013) Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 19:941\u2013946","journal-title":"Mult Scler"},{"key":"9160_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302","journal-title":"Ann Neurol"},{"key":"9160_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1352458515591071","volume":"22","author":"\u00c1 Cobo-Calvo","year":"2016","unstructured":"Cobo-Calvo \u00c1, Sep\u00falveda M, Bernard-Valnet R et al (2016) Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler 22:312\u2013319","journal-title":"Mult Scler"},{"key":"9160_CR15","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","volume":"80","author":"R Marignier","year":"2013","unstructured":"Marignier R, Bernard-Valnet R, Giraudon P et al (2013) Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 80:2194\u20132200","journal-title":"Neurology"},{"key":"9160_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","volume":"263","author":"M Sep\u00falveda","year":"2016","unstructured":"Sep\u00falveda M, Armangue T, Martinez-Hernandez E et al (2016) Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 263:1349\u20131360","journal-title":"J Neurol"},{"key":"9160_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/jnnp-2015-312676","volume":"87","author":"K Kaneko","year":"2016","unstructured":"Kaneko K, Sato DK, Nakashima I et al (2016) Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry 87:1257\u20131259","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9160_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","volume":"89","author":"K Kaneko","year":"2018","unstructured":"Kaneko K, Sato DK, Nakashima I et al (2018) CSF cytokine profile in MOG-IgG + neurological disease is similar to AQP4-IgG + NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89:927\u2013936","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9160_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0387-7604(12)80271-3","volume":"14","author":"M Hasegawa","year":"1992","unstructured":"Hasegawa M, Houdou S, Mito T et al (1992) Development of myelination in the human fetal and infant cerebrum: a myelin basic protein immunohistochemical study. Brain Dev 14:1\u20136","journal-title":"Brain Dev"},{"key":"9160_CR20","doi-asserted-by":"publisher","first-page":"16480","DOI":"10.1073\/pnas.1117943109","volume":"109","author":"DJ Miller","year":"2012","unstructured":"Miller DJ, Duka T, Stimpson CD et al (2012) Prolonged myelination in human neocortical evolution. Proc Natl Acad Sci 109:16480\u201316485","journal-title":"Proc Natl Acad Sci"},{"key":"9160_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1352458515587751","volume":"22","author":"C Fernandez-Carbonell","year":"2016","unstructured":"Fernandez-Carbonell C, Vargas-Lowy D, Musallam A et al (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 22:174\u2013184","journal-title":"Mult Scler"},{"key":"9160_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","volume":"71","author":"A McKeon","year":"2008","unstructured":"McKeon A, Lennon VA, Lotze T et al (2008) CNS aquaporin-4 autoimmunity in children. Neurology 71:93\u2013100","journal-title":"Neurology"},{"key":"9160_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis J, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195\u2013205","journal-title":"Ann Rheum Dis"},{"key":"9160_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.clim.2015.04.005","volume":"161","author":"MK Verheul","year":"2015","unstructured":"Verheul MK, Fearon U, Trouw LA, Veale DJ (2015) Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol 161:2\u201310","journal-title":"Clin Immunol"},{"key":"9160_CR25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J et al (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79:1368\u20131374","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9160_CR26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849","journal-title":"Brain"},{"key":"9160_CR27","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","volume":"2","author":"P Waters","year":"2015","unstructured":"Waters P, Woodhall M, O\u2019Connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol NeuroInflammation 2:e89","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"9160_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","volume":"14","author":"P Peschl","year":"2017","unstructured":"Peschl P, Schanda K, Zeka B et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation 14:208","journal-title":"J Neuroinflammation"},{"key":"9160_CR29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awy010","volume":"141","author":"R Wilson","year":"2018","unstructured":"Wilson R, Makuch M, Kienzler A-K et al (2018) Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. Brain 141:1063\u20131074","journal-title":"Brain"},{"key":"9160_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134","journal-title":"J Neuroinflammation"}],"updated-by":[{"DOI":"10.1007\/s00415-019-09215-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9160-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9160-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9160-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:39:32Z","timestamp":1577993972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9160-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["9160"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9160-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"28 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Cobo-Calvo, Sepulveda, d\u2019Indy, Armangu\u00e9 and Ruiz report no disclosures. Maillart has received consulting and lecturing fees, and travel grants from Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma, and research support from Novartis and Roche. Audoin reports no disclosures. Zephir reports no disclosures. Jonathan Ciron serves on scientific advisory board for Merck Serono and Roche, and has received funding for travel and honoraria from Biogen, Novartis, Genzyme, Teva Pharmaceuticals, Merck Serono and Roche, with no relation with the submitted work. Ayrignac and Thouvenot report no disclosures. Montcuquet has received funding for travel from Merck Serono, Teva, Novartis, Sanofi-Genzyme and Biogen. Sol\u00e0 Valls received consulting and travel grants from Biogen Idec, Genzyme-Sanofi, Merck Serono, and Bayer-Schering. Llufriu reports no disclosures. Papeix reports no disclosures. Biotti has received consulting and lecturing fees, and travel grants from Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma. Durand-Dubief serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva. Collongues has received honoraria for consulting or presentation from Biogen Idec, Almirall, Novartis, Merck Serono, LFB, Teva Pharma, Sanofi-Genzyme, Roche, and is a member of the editorial board of the Journal de la Ligue Fran\u00e7aise contre la Scl\u00e9rose en plaques, with no relation with the submitted work. Labauge reports no disclosure. Deschamps has received travels grants from Biogen Idec. De Seze reports no disclosures. Vukusic has received consulting and lecturing fees, travel grants and research support from Biogen, Geneuro, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharm. Blanco reports no disclosures. Saiz has received travel funding and\/or speaker honoraria from Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries, Novartis and Roche. Marignier has received consulting and lecturing fees, travel grants and research support from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}